Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Immunology

• Publication date

  2011-08-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.1101135PMID 21742972
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Invariant NKT cells

  2013cited by this paper
• antibody therapy is critically dependent on CD27 costimulation Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal

  2013cited by this paper
• CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

  2011cited by this paper
• An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.

  2011influential reference
• Presentation of Soluble Antigens to CD8+ T Cells by CpG Oligodeoxynucleotide-Primed Human Naive B Cells

  2011cited by this paper
• CD20 as a target for therapeutic type I and II monoclonal antibodies.

  2010cited by this paper
• Genetic variation, Fcγ receptors, KIRs and infection: the evolution of autoimmunity.

  2010cited by this paper
• Effector and regulatory B cells: modulators of CD4+ T cell immunity

  2010cited by this paper
• Anti-CD20 monoclonal antibodies: historical and future perspectives

  2010cited by this paper
• Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Ligation of CD11c during vaccination promotes germinal centre induction and robust humoral responses without adjuvant

  2010cited by this paper
• FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications

  2010cited by this paper
• Differential Recruitment of Activating and Inhibitory FcγRII during Phagocytosis

  2010cited by this paper
• A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (MAb), Chi Lob 7/4.

  2010cited by this paper
• Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.

  2009cited by this paper
• Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

  2009cited by this paper
• Absence of Tapasin Alters Immunodominance against a Lymphocytic Choriomeningitis Virus Polytope

  2009cited by this paper
• Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.

  2009cited by this paper
• Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV.

  2008cited by this paper
• The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.

  2008cited by this paper
• Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

  2008cited by this paper
• Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling*

  2008cited by this paper
• Invariant NKT Cells Promote CD8+ Cytotoxic T Cell Responses by Inducing CD70 Expression on Dendritic Cells1

  2008cited by this paper
• CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses

  2008cited by this paper
• Antibodies, Fc receptors and cancer.

  2007cited by this paper
• Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective.

  2007cited by this paper
• Trastuzumab--mechanism of action and use in clinical practice.

  2007cited by this paper
• IgEb immune complexes activate macrophages through FcgammaRIV binding.

  2007cited by this paper
• Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

  2007cited by this paper
• Prospect of Targeting the CD40 Pathway for Cancer Therapy

  2007influential reference
• IgEb immune complexes activate macrophages through FcγRIV binding

  2007cited by this paper
• Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy

  2006cited by this paper
• Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

  2006cited by this paper
• FcgammaRIV: a novel FcR with distinct IgG subclass specificity.

  2005influential reference
• B Cell Receptor (BCR) Cross-Talk: CD40 Engagement Creates an Alternate Pathway for BCR Signaling That Activates IκB Kinase/IκBα/NF-κB without the Need for PI3K and Phospholipase Cγ 1

  2005cited by this paper
• FcγRIV : A novel FcR with distinct IgG subclass specificity

  2005cited by this paper
• B cell receptor (BCR) cross-talk: CD40 engagement creates an alternate pathway for BCR signaling that activates I kappa B kinase/I kappa B alpha/NF-kappa B without the need for PI3K and phospholipase C gamma.

  2005cited by this paper
• Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding

  2005cited by this paper
• The role of the CD40 pathway in the pathogenesis and treatment of cancer.

  2004cited by this paper
• The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy

  2004cited by this paper
• Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.

  2003cited by this paper
• FcγRs Modulate Cytotoxicity of Anti-Fas Antibodies: Implications for Agonistic Antibody-Based Therapeutics1

  2003cited by this paper
• T Cell Immunity to Lymphoma Following Treatment with Anti-CD40 Monoclonal Antibody1

  2002cited by this paper
• Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

  2002cited by this paper
• CD40 ligation for immunotherapy of solid tumours.

  2001cited by this paper
• Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154

  2001cited by this paper
• CD40‐CD40 ligand

  2000cited by this paper
• Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

  2000cited by this paper
• Radioimmunotherapy in the π-BCL1 B cell Lymphoma Model: Efficacy Depends on More Than Targeted Irradiation Alone

  2000cited by this paper
• Signaling through CD40 enhances cytotoxic T lymphocyte generation by CD8+ T cells from mice bearing large tumors

  1999cited by this paper
• Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40

  1999cited by this paper
• Minimal cross-linking and epitope requirements for CD40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells.

  1999cited by this paper
• CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help

  1999cited by this paper
• CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism.

  1999cited by this paper
• CD40 and CD154 in cell-mediated immunity.

  1998cited by this paper
• Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors.

  1998cited by this paper
• Augmented humoral and anaphylactic responses in FcγRII-deficient mice

  1996cited by this paper
• Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice.

  1996cited by this paper
• FcR gamma-chain is essential for both surface expression and function of human Fc gamma RI (CD64) in vivo.

  1996cited by this paper

• Recombinant spider silk functionalized with a CD40 agonist shows improved capability to activate human B cells in vitro - A novel module for cancer immunotherapy.

  2025cites this paper
• The ETS-family transcription factor PU.1 is a critical regulator of the inhibitory Fcγ receptor IIB expression in humans

  2025cites this paper
• Exploratory Immunohistochemical Profiling of FOXP3, PD-1 and CD32B in Resectable Lung Adenocarcinoma

  2025cites this paper
• A bispecific anti-MUC16/anti-death receptor 5 antibody achieves effective and tumor-selective death receptor 5-mediated tumor regression

  2025influential citation
• Harnessing multivalency and FcγRIIB engagement to augment anti-CD27 immunotherapy

  2025cites this paper
• Bispecific antibody targeting CD40 and HER2 potentiates therapeutic efficacy by reprogramming macrophages within the tumour microenvironment

  2025cites this paper
• Structure-guided disulfide engineering restricts antibody conformation to elicit TNFR agonism

  2025cites this paper
• Targeting Myeloid Cells for Cancer Immunotherapy

  2025cites this paper
• FcγRIIB (CD32B) antibodies enhance immune responses through activating FcγRs

  2025cites this paper
• Fcγ-Receptor-Independent Controlled Activation of CD40 Canonical Signaling by Novel Therapeutic Antibodies for Cancer Therapy

  2024cites this paper
• Genetically engineered IgG1 and nanobody oligomers acquire strong intrinsic CD40 agonism

  2024cites this paper
• Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations

  2024cites this paper
• Clinical landscape of macrophage-reprogramming cancer immunotherapies

  2024cites this paper
• Targeting TNFRSF25 by agonistic antibodies and multimeric TL1A proteins co-stimulated CD8+ T cells and inhibited tumor growth

  2024cites this paper
• Underappreciated layers of antibody-mediated immune synapse architecture and dynamics

  2024cites this paper
• PD-1 antibody interactions with Fc gamma receptors enable PD-1 agonism to inhibit T cell activation - therapeutic implications for autoimmunity.

  2024cites this paper
• Tumor necrosis factor superfamily signaling: life and death in cancer

  2024cites this paper
• The application of antibody-based agents in cancer therapy based on their mechanisms of action

  2024cites this paper
• Fcγ receptor binding is required for maximal immunostimulation by CD70-Fc

  2023cites this paper
• Cell targeting and immunostimulatory properties of a novel Fcγ-receptor-independent agonistic anti-CD40 antibody in rhesus macaques

  2023cites this paper
• Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy

  2023cites this paper
• Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists

  2023cites this paper
• Fcγ receptors and immunomodulatory antibodies in cancer

  2023cites this paper
• Serum immunoglobulin and the threshold of Fc receptor-mediated immune activation

  2023cites this paper
• Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade

  2023cites this paper
• Agonist antibodies for cancer immunotherapy: History, Hopes and Challenges

  2023cites this paper
• The antitumor activities of anti-CD47 antibodies require Fc-FcγR interactions.

  2023cites this paper
• Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives

  2023cites this paper
• Reducing affinity as a strategy to boost immunomodulatory antibody agonism

  2023cites this paper
• EGFR-selective activation of CD27 co-stimulatory signaling by a bispecific antibody enhances anti-tumor activity of T cells

  2023cites this paper
• The Antitumor Activities of Anti-CD47 Antibodies Require Fc-FcγR interactions

  2023cites this paper
• Effect of posttranslational modifications and subclass on IgG activity: from immunity to immunotherapy

  2023cites this paper
• Advances in antibody-based therapy in oncology

  2023cites this paper
• Anti–PD-1 antibodies recognizing the membrane-proximal region are PD-1 agonists that can down-regulate inflammatory diseases

  2023influential citation
• Fc gamma receptors promote antibody-induced LILRB4 internalization and immune regulation of monocytic AML

  2023cites this paper
• Modulation of urelumab glycosylation separates immune stimulatory activity from organ toxicity

  2022cites this paper
• Fcγ receptor–mediated cross-linking codefines the immunostimulatory activity of anti-human CD96 antibodies

  2022cites this paper
• Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies

  2022cites this paper
• The secreted protein Cowpox Virus 14 contributes to viral virulence and immune evasion by engaging Fc-gamma-receptors

  2022cites this paper
• Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy

  2022cites this paper
• HINGEneering IgG for enhanced immune activation

  2022cites this paper
• Tailoring biomaterials and applications targeting tumor-associated macrophages in cancers

  2022cites this paper
• FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms

  2022cites this paper
• Hinge disulfides in human IgG2 CD40 antibodies modulate receptor signaling by regulation of conformation and flexibility

  2022cites this paper
• Avidity in antibody effector functions and biotherapeutic drug design

  2022cites this paper
• A multispecific anti-CD40 DARPin® construct induces tumor-selective CD40 activation and tumor regression.

  2022cites this paper
• Zooming in on dendritic cells for CD40 agonists

  2022cites this paper
• HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy

  2022cites this paper
• Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering

  2022influential citation
• Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments

  2022cites this paper
• Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting

  2022cites this paper
• Phenotypic Characterization of Liver Sinusoidal Endothelial Cells on the Human Liver-Chip for Potential in vitro Therapeutic Antibody Pharmacology Applications

  2022cites this paper
• Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking

  2022influential citation
• CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies

  2021cites this paper
• Development of Therapeutic Antibodies and Modulating the Characteristics of Therapeutic Antibodies to Maximize the Therapeutic Efficacy

  2021cites this paper
• Density of Conjugated Antibody Determines the Extent of Fc Receptor Dependent Capture of Nanoparticles by Liver Sinusoidal Endothelial Cells.

  2021cites this paper
• Receptor Oligomerization and Its Relevance for Signaling by Receptors of the Tumor Necrosis Factor Receptor Superfamily

  2021cites this paper
• Mechanismen der IgG-Aktivität in der Therapie von Autoimmunität und Krebs

  2021cites this paper
• Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity

  2021cites this paper
• FcγRIIB is a T cell checkpoint in antitumor immunity

  2021cites this paper
• Agonistic CD40 Antibodies in Cancer Treatment

  2021cites this paper
• Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer

  2021cites this paper
• APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application

  2021cites this paper
• The Current Landscape of Antibody-based Therapies in Solid Malignancies

  2021cites this paper
• Analysis of FcγR-Dependent Agonism of Antibodies Specific for Receptors of the Tumor Necrosis Factor (TNF) Receptor Superfamily (TNFRSF).

  2021cites this paper
• Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy

  2021cites this paper
• TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity

  2021cites this paper
• How to select IgG subclasses in developing anti-tumor therapeutic antibodies

  2020cites this paper
• Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity

  2020influential citation
• CD40 Agonist Antibodies in Cancer Immunotherapy.

  2020cites this paper
• Domain binding and isotype dictate the activity of anti-human OX40 antibodies

  2020cites this paper
• Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs

  2020cites this paper
• Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy

  2020cites this paper
• Tumor localized agonistic anti-CD40 therapy and beyond

  2020cites this paper
• Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity

  2020cites this paper
• Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy

  2020cites this paper
• Isotype selection for antibody‐based cancer therapy

  2020cites this paper
• Targeting tumor‐associated macrophages: A potential treatment for solid tumors

  2020cites this paper
• Reprogramming the Constant Region of Immunoglobulin G Subclasses for Enhanced Therapeutic Potency against Cancer

  2020cites this paper
• FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells

  2020cites this paper
• Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies

  2020cites this paper
• Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment

  2020cites this paper
• Defining and targeting combination immunotherapies in mouse models of cancer

  2019cites this paper
• CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches

  2019cites this paper
• Ligand-Blocking and Membrane-Proximal Domain Targeting Anti-OX40 Antibodies Mediate Potent T Cell-Stimulatory and Anti-Tumor Activity.

  2019cites this paper
• On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy

  2019cites this paper
• Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility

  2019cites this paper
• Antibody Structure and Function: The Basis for Engineering Therapeutics

  2019cites this paper
• Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering

  2019cites this paper
• Targeted APC Activation in Cancer Immunotherapy to Enhance the Abscopal Effect

  2019cites this paper
• Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB

  2019cites this paper
• Impact of Human FcγR Gene Polymorphisms on IgG-Triggered Cytokine Release: Critical Importance of Cell Assay Format

  2019cites this paper
• Role of FcγRs in Antibody-Based Cancer Therapy.

  2019cites this paper
• TNFRSF receptor-specific antibody fusion proteins with targeting controlled FcγR-independent agonistic activity

  2019cites this paper
• Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity

  2019cites this paper
• Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy

  2018cites this paper
• Targeted delivery of CD 40 L promotes restricted activation of antigen-presenting cells and induction of cancer cell

  2018cites this paper
• FcγR interaction is not required for effective anti‐PD‐L1 immunotherapy but can add additional benefit depending on the tumor model

  2018cites this paper
• Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy

  2018cites this paper
• FcγRII-binding Centyrins mediate agonism and antibody-dependent cellular phagocytosis when fused to an anti-OX40 antibody

  2018cites this paper